Literature DB >> 11313378

Modulation of CD8+ T cell response to antigen by the levels of self MHC class I.

F R Santori1, I Arsov, S Vukmanović.   

Abstract

The response of H-Y-specific TCR-transgenic CD8(+) T cells to Ag is characterized by poor proliferation, cytolytic activity, and IFN-gamma secretion. IFN-gamma secretion, but not cytotoxic function, can be rescued by the B7.1 molecule, suggesting that costimulation can selectively enhance some, but not all, effector CD8(+) T cell responses. Although the H-Y epitope binds H-2D(b) relatively less well than some other epitopes, it can induce potent CTL responses in nontransgenic mice, suggesting that the observed poor responsiveness of transgenic CD8(+) T cells cannot be ascribed to the epitope itself. Previously reported reactivity of this TCR to H-2A(b) is also not the cause of the poor responsiveness of the H-Y-specific CD8(+) T cells, as H-Y-specific CD8(+) T cells obtained from genetic backgrounds lacking H-2A(b) also responded poorly. Rather, reducing the levels of H-2(b) class I molecules by breeding the mice to (C57BL/6 x B10.D2)F(1) or TAP1(+/-) backgrounds partially restored cytotoxic activity and enhanced proliferative responses. These findings demonstrate that the self MHC class I gene dosage may regulate the extent of CD8(+) T cell responsiveness to Ag.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313378     DOI: 10.4049/jimmunol.166.9.5416

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  2 in total

Review 1.  Quantitative challenges in understanding ligand discrimination by alphabeta T cells.

Authors:  Ofer Feinerman; Ronald N Germain; Grégoire Altan-Bonnet
Journal:  Mol Immunol       Date:  2007-09-06       Impact factor: 4.407

2.  Disparate epitopes mediating protective heterologous immunity to unrelated viruses share peptide-MHC structural features recognized by cross-reactive T cells.

Authors:  Zu T Shen; Tina T Nguyen; Keith A Daniels; Raymond M Welsh; Lawrence J Stern
Journal:  J Immunol       Date:  2013-10-14       Impact factor: 5.422

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.